A 25-year study of 22,000 Britons reveals that men with cardiovascular disease face a significantly higher risk of developing and dying from cancer compared to women, with smoking, obesity, and alcohol identified as key contributing factors.
Eli Lilly and Novo Nordisk both beat Q2 estimates and raised outlooks, but Wall Street rewarded Lilly while punishing Novo over pipeline and market share concerns in the $100B+ obesity drug sector.
New research from the University of Toronto challenges long-held nutritional beliefs by showing that consuming three daily servings of full-fat dairy does not negatively affect weight, body composition, or cholesterol levels.
Nearly 200 deaths and over 150,000 adverse reactions have been linked to anti-obesity drugs Mounjaro, Wegovy, Ozempic, and Saxenda in the UK, according to data from the MHRA Yellow Card scheme.
WHO Director-General Tedros Adhanom Ghebreyesus accused major ultra-processed food (UPF) corporations of obstructing global efforts to combat obesity by suing governments over public health measures like warning labels and taxes, costing billions in legal and healthcare expenses.
Novo Nordisk faces a lawsuit from shareholders alleging misleading statements about its obesity drug CagriSema's clinical trial, leading to a significant market value drop. A federal judge has allowed parts of the lawsuit to proceed.
Australia's Therapeutic Goods Administration (TGA) has warned about a "rare but severe" eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), linked to type 2 diabetes and obesity treatments like Ozempic and Mounjaro. The warning, based on 36 reported cases, advises patients to seek urgent medical attention for sudden vision loss but not to stop treatment without consulting a doctor.
Australia's TGA has issued a safety warning for GLP-1 drugs like Ozempic, Mounjaro, and Wegovy, linking them to non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye disorder causing potential permanent vision loss. Experts advise caution but not panic, stressing consultation with prescribers.
Eli Lilly announced it will file for approval of its next-generation obesity drug, retatrutide, in Q1 2027, later than previously stated. This follows successful late-stage trials showing significant weight loss in adults with obesity, Type 2 diabetes, and cardiovascular disease.
Vivani Medical is developing a GLP-1 implant for long-term weight loss maintenance, potentially reducing side effects and injection fatigue. The device, an experimental semaglutide implant, aims for twice-yearly or annual administration, complementing existing GLP-1 treatments. However, it faces clinical trials, regulatory hurdles, and questions about cost and physician adoption.
A new American Heart Association study shows US obesity prevalence rose from 30% to 41% between 1999-2023. Abdominal obesity increased from 48% to 61%. The study highlights spikes in severe and abdominal obesity, particularly among youth and women.
A new study presented at the European Society of Human Reproduction and Embryology in London reveals that men's total testosterone levels have declined by 54% between 1972 and 2019. Scientists attribute this to factors including obesity, diabetes, environmental chemicals, and global heating, warning of a male fertility crisis.
L'obesità in Italia è in aumento, specialmente tra le donne giovani (18-34 anni) con un +75% in 10 anni. Allarmanti anche i dati sui minori (26%) e le conseguenze sulla fertilità femminile.
A growing number of Indian couples are using GLP-1 injections like Ozempic and Mounjaro for rapid weight loss before their weddings, driven by societal pressure and social media expectations. Medical professionals express concern over misuse, potential counterfeits, and health risks.
A growing number of individuals are using GLP-1 injections like Ozempic and Mounjaro for rapid weight loss to meet conventional beauty standards for weddings, rather than for genuine health concerns. This trend alarms medical professionals due to potential health risks, counterfeit drugs, and unsustainable results.
A study found that many adults with obesity have cholesterol and blood pressure levels indistinguishable from those of healthy weight, largely due to statins and blood pressure medication. The findings are particularly notable in individuals aged 40 and over, suggesting a convergence of cardiovascular risk factors.
A study published in The Lancet reveals that many obese adults, particularly those over 40, now have cholesterol and blood pressure levels comparable to healthy-weight individuals, largely due to the widespread use of statins and blood pressure medications. Researchers examined data from nearly 1 million adults across several countries, finding that these risk factors have converged, though obesity still poses risks for younger adults and other health conditions.
Medicare has begun covering obesity drugs for the first time, a significant policy shift offering access to millions of older Americans. Walmart and CVS Health are launching nationwide efforts to educate patients and provide support, including pharmacy consultations and virtual visits, to navigate the new coverage and manage treatments.
Medicare is launching the Bridge demonstration program to cover GLP-1 obesity drugs for eligible beneficiaries with a $50 monthly copay, a first for the program. This temporary initiative, set to expire in 2027, could unlock millions of new patients for Novo Nordisk and Eli Lilly, but raises concerns about healthcare system strain and long-term patient access.
Damien and Jessica O'Brien, parents of 7-year-old Casper O'Brien, are charged with second-degree murder, torture, and child abuse after their son's death from dilated cardiomyopathy, exacerbated by severe obesity due to a diet of only snack foods.
Medicare's Bridge program starts covering obesity drugs for eligible beneficiaries with a $50 monthly copay, but 82% of older Americans are unaware of this new coverage.
El Dr. López-Nava aboga por un enfoque integral para la obesidad, combinando fármacos como Ozempic con cambios en el estilo de vida. Advierte que los medicamentos son una ayuda temporal y sin modificación de hábitos, el peso se recupera.
A study in The Lancet reveals new obesity diagnoses are rising fastest among adults in their 20s and 30s in England, with rates up nearly 20% since 2019-20. Experts link this trend to unhealthy food environments, advertising, and socioeconomic pressures.
A single 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide through the FDA's compassionate use program. The unusual case has sparked speculation about the patient's identity, with questions raised if it could be former President Donald Trump.
